Stock Report: Zimmer Biomet (ZBH)

Takeaway: We added Zimmer Biomet to Investing Ideas on the short side on 9/4.

Stock Report: Zimmer Biomet (ZBH) - z 1 ZBH table 9 11 15

 

THE HEDGEYE EDGE

 

Zimmer Biomet (ZBH) is in the crosshairs of a number of our Healthcare themes. 

 

The first, and specific to ZBH, is our view that the demographic drivers of knee joint replacement are well past peak and in a secular decline.  We did what we believe is a thorough analysis of the contribution of aging and obesity to the population of people with severe osteoarthritis of the knee.  What we found was a market that peaked in 1990s and has likely drawn down the majority of eligible patients as implant rates per capita rose faster than the underlying patient population growth. 

 

Second, affordability of medical spending has peaked in the United States with deflationary pressures mounting and being expressed through policy changes alongside the broadening adoption of IT systems.  Better information systems and price transparency are likely to have an increasingly negative impact on device costs with orthopedic devices sitting at the top of the spending list.  

 

On a related note, Medicare recently initiated an aggressive global payment policy (CCRJ) which we expect to create a strong incentive for providers to pressure device costs. 

 

We believe the #ACATaper is emerging over the coming months as the newly insured revert to spending levels similar levels as seen with typical insured populations.  We’ve documented several instances where the newly insured consumed medical care at elevated rates during the initial rollout of this historic program, with evidence that knee replacement volume saw a dramatic increase.

 

Lastly, the Biomet merger (while accretive) is not the solution for ZBH shares.  Cost synergies are rarely a positive when organic growth is slowing.  

TIMESPAN

INTERMEDIATE TERM (TREND) (the next 3 months or more)

 

We do not expect fundamental misses of dramatic size in the intermediate term.  However, employment growth slowing and fears of a recession will certainly dampen investor appetite for what is viewed as an elective procedure.  

 

 

LONG-TERM (TAIL) (the next 3 years or less)

 

Our team's long-term view calls for slowing/declining unit volume and deteriorating pricing.  The impact to gross margins should be significant with very little spending flexibility within the organization. 

ONE-YEAR TRAILING CHART

Stock Report: Zimmer Biomet (ZBH) - z 2 ZBH chart 9 11 15


SECTOR SPOTLIGHT | Live Q&A with Healthcare Analyst Tom Tobin Today at 2:30PM ET

Join us for this edition of Sector Spotlight with Healthcare analyst Tom Tobin and Healthcare Policy analyst Emily Evans.

read more

Ouchy!! Wall Street Consensus Hit By Epic Short Squeeze

In the latest example of what not to do with your portfolio, we have Wall Street consensus positioning...

read more

Cartoon of the Day: Bulls Leading the People

Investors rejoiced as centrist Emmanuel Macron edged out far-right Marine Le Pen in France's election day voting. European equities were up as much as 4.7% on the news.

read more

McCullough: ‘This Crazy Stat Drives Stock Market Bears Nuts’

If you’re short the stock market today, and your boss asks why is the Nasdaq at an all-time high, here’s the only honest answer: So far, Nasdaq company earnings are up 46% year-over-year.

read more

Who's Right? The Stock Market or the Bond Market?

"As I see it, bonds look like they have further to fall, while stocks look tenuous at these levels," writes Peter Atwater, founder of Financial Insyghts.

read more

Poll of the Day: If You Could Have Lunch with One Fed Chair...

What do you think? Cast your vote. Let us know.

read more

Are Millennials Actually Lazy, Narcissists? An Interview with Neil Howe (Part 2)

An interview with Neil Howe on why Boomers and Xers get it all wrong.

read more

6 Charts: The French Election, Nasdaq All-Time Highs & An Earnings Scorecard

We've been telling investors for some time that global growth is picking up, get long stocks.

read more

Another French Revolution?

"Don't be complacent," writes Hedgeye Managing Director Neil Howe. "Tectonic shifts are underway in France. Is there the prospect of the new Sixth Republic? C'est vraiment possible."

read more

Cartoon of the Day: The Trend is Your Friend

"All of the key trending macro data suggests the U.S. economy is accelerating," Hedgeye CEO Keith McCullough says.

read more

A Sneak Peek At Hedgeye's 2017 GDP Estimates

Here's an inside look at our GDP estimates versus Wall Street consensus.

read more

Cartoon of the Day: Green Thumb

So far, 64 of 498 companies in the S&P 500 have reported aggregate sales and earnings growth of 6.1% and 16.8% respectively.

read more